Answers are grounded in this paper and cite their sources.
Recent studies have found HMGB1 as a potential and valuable bio-marker for NSCLC. Many targeted therapies have been developed with effective clinical proofs; however treatment responses are typically short-lived because of the frequent mutation of target genes. HMGB1 which has been targeted in several cancer therapies for its conservative feature would possess a potential clinical value for NSCLC treatment.
No takes yet. Share an insight, caveat, or question.
Zhenbo Tu (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: